{"name": "Inspiration Biopharmaceuticals",
 "permalink": "inspiration-biopharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/inspiration-biopharmaceuticals",
 "homepage_url": "http://www.inspirationbio.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "888-808-0896",
 "description": "",
 "created_at": "Tue Oct 04 06:06:25 UTC 2011",
 "updated_at": "Tue Oct 04 06:07:08 UTC 2011",
 "overview": "\u003Cp\u003EInspiration Biopharmaceuticals, Inc. develops recombinant blood coagulation factor products for the treatment of hemophilia. Its product candidates include IB1001, an intravenous recombinant factor IX for the acute and preventative treatment of bleeding in individuals with hemophilia B; and OBI-1, an intravenous recombinant porcine factor VIII (FVIII) for the treatment of individuals who have developed inhibitors against human FVIII and for individuals with acquired hemophilia A. The company also has preclinical programs that focus on human recombinant factor VIIa for individuals with either hemophilia A or B who have developed inhibitors, and individuals with factor VII deficiency; human recombinant FVIII to treat individuals with hemophilia A. Inspiration Biopharmaceuticals has a strategic partnership with Ipsen SA. The company was founded in 2004 and is based in Laguna Niguel, California. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       48],
      "assets/images/resized/0015/6649/156649v1-max-150x150.png"],
     [[229,
       74],
      "assets/images/resized/0015/6649/156649v1-max-250x250.png"],
     [[229,
       74],
      "assets/images/resized/0015/6649/156649v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Michael",
      "last_name": "Griffith",
      "permalink": "michael-griffith",
      "image": null}},
   {"is_past": false,
    "title": "Executive Vice President and COO",
    "person":
     {"first_name": "Andrew",
      "last_name": "Grethlein",
      "permalink": "andrew-grethlein",
      "image": null}},
   {"is_past": false,
    "title": "Senior Vice President and CFO",
    "person":
     {"first_name": "Gordon",
      "last_name": "Busenbark",
      "permalink": "gordon-busenbark",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "28202 Cabot Road",
    "address2": "Suite 300 ",
    "zip_code": "92677",
    "city": "Laguna Niguel",
    "state_code": "CA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Inspiration nabs $35M milestone on EMA hemophilia review",
    "stoned_year": 2011,
    "stoned_month": 10,
    "stoned_day": 3,
    "source_url": "http://www.fiercebiotech.com/story/inspiration-nabs-35m-milestone-ema-hemophilia-review/2011-10-03?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Inspiration nabs $35M milestone on EMA hemophilia review",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Inspiration Biopharmaceuticals",
      "permalink": "inspiration-biopharmaceuticals"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}